Literature DB >> 20018269

Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model.

Rui Fang1, Hanli Feng, Hao Nie, Lixia Wang, Pan Tu, Qiqi Song, Yanqin Zhou, Junlong Zhao.   

Abstract

Toxoplasma gondii is a protozoan parasite causing toxoplasmosis to almost one-third of population all over the world. One of the most efficient ways to control this disease is immunization. However, so far, there is no effective vaccine available against this pathogen. Recently, a baculovirus pseudotype with vesicular stomatitis virus G protein (Bac-VSV-G) was found to efficiently transduce and express transgenes on mammalian cells, so it was considered as an excellent expressing vector. In this study, the value of Bac-VSV-G in delivering T. gondii antigen was investigated. T. gondii SAG1 gene was cloned into Bac-VSV-G, and recombinant baculovirus BV-G-SAG1 was obtained. Indirect immunofluorescence test showed BV-G-SAG1 was efficiently transduced and expressed in pig kidney cells. Then BALB/c mice were immunized with BV-G-SAG1 at different doses (1 x 10(8), 1 x 10(9), and 1 x 10(10)PFU/mouse) and challenged with T. gondii RH strain tachyzoites after immunization. The levels of specific T. gondii antibody, interferon (IFN)-gamma, IL-4, IL-10 expression and release, and the survival rate of treated mice were evaluated. Compared with the mice immunized with DNA vaccine (pcDNA/SAG1) encoding the same gene, BV-G-SAG1 induced higher levels of specific T. gondii antibody and (IFN)-gamma expression with dose-dependent manner and the survival rate of mice with BV-G-SAG1 was significantly improved. These results indicated that pseudotype baculovirus-mediated gene delivery can be utilized as an alternative strategy to develop new generation of vaccines against T. gondii infection. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018269     DOI: 10.1016/j.vaccine.2009.12.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Baculovirus as a vaccine vector.

Authors:  Hsin-Yu Lu; Yi-Hsuan Chen; Hung-Jen Liu
Journal:  Bioengineered       Date:  2012-06-18       Impact factor: 3.269

2.  Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.

Authors:  Chikako Ono; Akinori Ninomiya; Satomi Yamamoto; Takayuki Abe; Xiauyu Wen; Takasuke Fukuhara; Miwa Sasai; Masahiro Yamamoto; Tatsuya Saitoh; Takashi Satoh; Taro Kawai; Ken J Ishii; Shizuo Akira; Toru Okamoto; Yoshiharu Matsuura
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Comparative evaluation of immunization with recombinant protein and plasmid DNA vaccines of fusion antigen ROP2 and SAG1 from Toxoplasma gondii in mice: cellular and humoral immune responses.

Authors:  Wen-Shu Li; Qing-Xin Chen; Ju-Xiu Ye; Zi-Xin Xie; Jun Chen; Li-Fang Zhang
Journal:  Parasitol Res       Date:  2011-03-15       Impact factor: 2.289

4.  Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites.

Authors:  Yong-Feng Fu; Meng Feng; Kenji Ohnishi; Tamon Kimura; Johbu Itoh; Xun-Jia Cheng; Hiroshi Tachibana
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

Review 5.  REVIEW OF DNA VACCINE APPROACHES AGAINST THE PARASITE TOXOPLASMA GONDII.

Authors:  Rosalie C Warner; Ryan C Chapman; Brianna N Davis; Paul H Davis
Journal:  J Parasitol       Date:  2021-11-01       Impact factor: 1.276

6.  Bombyx mori nucleopolyhedrovirus displaying neospora caninum antigens as a vaccine candidate against N. caninum infection in mice.

Authors:  Tatsuya Kato; Takahiro Otsuki; Mai Yoshimoto; Kohei Itagaki; Tetsuya Kohsaka; Yumino Matsumoto; Kazunori Ike; Enoch Y Park
Journal:  Mol Biotechnol       Date:  2015-02       Impact factor: 2.695

7.  A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice.

Authors:  Yimei Cao; Zengjun Lu; Pu Sun; Yuanfang Fu; Feipeng Tian; Xiaofang Hao; Huifang Bao; Xiangtao Liu; Zaixin Liu
Journal:  Virol J       Date:  2011-02-23       Impact factor: 4.099

8.  Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1.

Authors:  Érica Araújo Mendes; Flavio G Fonseca; Bárbara M Casério; Janaína P Colina; Ricardo Tostes Gazzinelli; Braulia C Caetano
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

9.  Virus-Like Nanoparticle Vaccine Confers Protection against Toxoplasma gondii.

Authors:  Dong Hun Lee; Su Hwa Lee; Ah Ra Kim; Fu Shi Quan
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

10.  Experimental Porcine Toxoplasma gondii Infection as a Representative Model for Human Toxoplasmosis.

Authors:  Julia Nau; Silvia Kathrin Eller; Johannes Wenning; Katrin Henrike Spekker-Bosker; Horst Schroten; Christian Schwerk; Andrea Hotop; Uwe Groß; Walter Däubener
Journal:  Mediators Inflamm       Date:  2017-08-13       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.